Glioblastoma, the most common and aggressive brain tumor with low survival rate,\nis dicult to be cured by neurosurgery or radiotherapy. Mounting evidence has reported the\nanti-inflammatory and anticancer eects of curcumin on several types of cancer in preclinical studies\nand clinical trials. To our knowledge, there is no platform or system that could be used to eectively\nand real-timely evaluate the therapeutic ecacy of curcumin for glioblastoma multiforme (GBM).\nIn this study, we constructed a lentivirus vector with triple-reporter genes (Fluc/GFP/tk) and transduced\ninto rat F98 glioblastoma cells to establish an orthotopic F98/FGT glioma-bearing rat model. In the\nmodel, the therapeutic ecacies for curcumin alone, radiation alone, and their combination were\nevaluated via noninvasive bioluminescent imaging and overall survival measurements. At the\ncell level, curcumin is capable of causing a G2/M cell cycle arrest and sensitizing the F98 cells\nto radiation. In animal model, curcumin synergistically enhances the eects of radiotherapy on\nsuppressing the growth of both transplanted glioma cells and in situ brain tumors, and extending\nthe overall survival periods longer than those of curcumin alone and radiation alone treatments.\nIn conclusion, we have demonstrated that curcumin may serve as a novel radiosensitizer to combine\nwith radiotherapy using the triple-reporter F98/FGT animal model for eective and simultaneous\nevaluation of therapeutic ecacy.
Loading....